Pre-infarction angina predicts thrombus burden in patients admitted for ST-segment elevation myocardial infarction

EuroIntervention

Volumn 7, Issue 12, 2012, Pages 1396-1405

  Ahmed, Tarek A N ^a,b   Sorgdrager, Bastiaan J ^a   Cannegieter, Suzanne C ^a   Van Der Laarse, Arnoud ^a   Schalij, Martin J ^a   Jukema, J Wouter ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ASSIUT UNIVERSITY   (Egypt)

Author keywords

Infarct size; Pre infarction angina; Primary percutaneous coronary intervention; ST elevation myocardial infarction; Thrombus grade; TIMI flow

Indexed keywords

CREATINE KINASE;

ADULT; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; CREATINE KINASE BLOOD LEVEL; FEMALE; GATED SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRE INFARCTION ANGINA; PREDICTION; RISK ASSESSMENT; SCORING SYSTEM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBECTOMY; THROMBOGENESIS; THROMBOLYSIS IN MYOCARDIAL INFARCTION; THROMBUS ASPIRATION; THROMBUS GRADE;

AGED; ANGINA PECTORIS; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ANGIOGRAPHY; CORONARY THROMBOSIS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; VENTRICULAR FUNCTION, LEFT;

EID: 84860764305     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV7I12A219     Document Type: Article

References (59)

1. Costantini CO, Stone GW, Mehran R, Aymong E, Grines CL, Cox DA, Stuckey T, Turco M, Gersh BJ, Tcheng JE, Garcia E, Griffin JJ, Guagliumi G, Leon MB, Lansky AJ. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. J Am Coll Cardiol. 2004;44:305-312. (Pubitemid 38950587)
2. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, Blumenthal RS, Lima JA. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998;97:765-772. (Pubitemid 28135339)
3. Hombach V, Grebe O, Merkle N, Waldenmaier S, Hoher M, Kochs M, Wohrle J, Kestler HA. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J. 2005;26:549-557. (Pubitemid 40461096)
4. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, Higashino Y, Fujii K, Minamino T. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996;93:223-228. (Pubitemid 26031478)
5. Vlaar PJ, Svilaas T, van der Horst IC, Diercks GF, Fokkema ML, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, Zijlstra F. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet. 2008;371:1915-1920. (Pubitemid 351778190)
6. Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP, Antman EM, Braunwald E. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001;103:2550-2554. (Pubitemid 32521963)
7. Thiele H, Schindler K, Friedenberger J, Eitel I, Furnau G, Grebe E, Erbs S, Linke A, Mobius-Winkler S, Kivelitz D, Schuler G. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation. 2008;118:49-57.
8. Napoli C, Liguori A, Chiariello M, Di IN, Condorelli M, Ambrosio G. New-onset angina preceding acute myocardial infarction is associated with improved contractile recovery after thrombolysis. Eur Heart J. 1998;19:411-419. (Pubitemid 28120721)
9. Ottani F, Galvani M, Ferrini D, Sorbello F, Limonetti P, Pantoli D, Rusticali F. Prodromal angina limits infarct size. A role for ischemic preconditioning. Circulation. 1995;91:291-297.
10. Solomon SD, Anavekar NS, Greaves S, Rouleau JL, Hennekens C, Pfeffer MA. Angina pectoris prior to myocardial infarction protects against subsequent left ventricular remodeling. J Am Coll Cardiol. 2004;43:1511-1514. (Pubitemid 38561325)
11. Colonna P, Cadeddu C, Montisci R, Ruscazio M, Selem AH, Chen L, Onnis E, Meloni L, Iliceto S. Reduced microvascular and myocardial damage in patients with acute myocardial infarction and preinfarction angina. Am Heart J. 2002;144:796-803. (Pubitemid 35335170)
12. Andreotti F, Pasceri V, Hackett DR, Davies GJ, Haider AW, Maseri A. Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction. N Engl J Med. 1996;334:7-12. (Pubitemid 26012497)
13. Liem SS, van der Hoeven BL, Oemrawsingh PV, Bax JJ, van der Bom JG, Bosch J, Viergever EP, van Rees C, Padmos I, Sedney MI, van Exel HJ, Verwey HF, Atsma DE, van der velde ET, Jukema JW, van der Wall EE, Schalij MJ. MISSION!: Optimization of acute and chronic care for patients with acute myocardial infarction. Am Heart J. 2007;153:14.e1-11.
14. van der Hoeven BL, Liem SS, Jukema JW, Suraphakdee N, Putter H, Dijkstra J, Atsma DE, Bootsma M, Zeppenfeld K, Oemrawsingh PV, van der Wall EE, Schalij MJ. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. J Am Coll Cardiol. 2008;51: 618-626. (Pubitemid 351186867)
15. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial. Circulation. 1993;87:38-52.
16. Miranda-Guardiola F, Rossi A, Serra A, Garcia B, Rumoroso JR, Iniguez A, Vaquerizo B, Triano JL, Sierra G, Bruguera J. Angiographic quantification of thrombus in ST-elevation acute myocardial infarction presenting with an occluded infarct-related artery and its relationship with results of percutaneous intervention. J Interv Cardiol. 2009;22:207-215.
17. Niccoli G, Spaziani C, Marino M, Pontecorvo ML, Cosentino N, Baca M, Porto I, Leone AM, Crea F. Effect of chronic Aspirin therapy on angiographic thrombotic burden in patients admitted for a first ST-elevation myocardial infarction. Am J Cardiol. 2010;105:587-591.
18. Sianos G, Papafaklis MI, Serruys PW. Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention. J Invasive Cardiol. 2010;22:6B-14B.
19. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med. 1985;312: 932-936.
20. Matsunari I, Fujino S, Taki J, Senma J, Aoyama T, Wakasugi T, Hirai J, Saga T, Yamamoto S, Tonami N. Quantitative rest technetium- 99m tetrofosmin imaging in predicting functional recovery after revascularization: Comparison with rest-redistribution thallium-201. J Am Coll Cardiol. 1997;29:1226-1233. (Pubitemid 27201939)
21. Burzotta F, Trani C, Romagnoli E, Mazzari MA, Rebuzzi AG, De VM, Garramone B, Giannico F, Niccoli G, Biondi-Zoccai GG, Schiavoni G, Mongiardo R, Crea F. Manual thrombus-aspiration improves myocardial reperfusion: the randomized evaluation of the effect of mechanical reduction of distal embolization by thrombus-aspiration in primary and rescue angioplasty (REMEDIA) trial. J Am Coll Cardiol. 2005;46:371-376. (Pubitemid 40966871)
22. Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, Michalis LK, Serruys PW. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol. 2007;50:573-583. (Pubitemid 47198999)
23. Kloner RA, Shook T, Przyklenk K, Davis VG, Junio L, Matthews RV, Burstein S, Gibson M, Poole WK, Cannon CP, McCabe CH, Braunwald E, TIMI 4 Investigators. Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? Circulation. 1995;91:37-45.
24. Nakagawa Y, Ito H, Kitakaze M, Kusuoka H, Hori M, Kuzuya T, Higashino Y, Fujii K, Minamino T. Effect of angina pectoris on myocardial protection in patients with reperfused anterior wall myocardial infarction: retrospective clinical evidence of "preconditioning". J Am Coll Cardiol. 1995;25:1076-1083.
25. Kloner RA, Yellon D. Does ischemic preconditioning occur in patients? J Am Coll Cardiol. 1994;24:1133-1142. (Pubitemid 24306429)
26. Cribier A, Korsatz L, Koning R, Rath P, Gamra H, Stix G, Merchant S, Chan C, Letac B. Improved myocardial ischemic response and enhanced collateral circulation with long repetitive coronary occlusion during angioplasty: a prospective study. J Am Coll Cardiol. 1992;20:578-586.
27. Iwakura K, Ito H, Kawano S, Shintani Y, Yamamoto K, Kato A, Ikushima M, Tanaka K, Kitakaze M, Hori M, Higashino Y, Fujii K. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Coll Cardiol. 2001;38:472-477. (Pubitemid 32721776)
28. Saito T, Kimura K, Kosuge M, Ishikawa T, Endo T, Sugano T, Hibi K, Nakagawa T, Nakatogawa T, Okuda J, Tochikubo O, Umemura S. Relation between the timing of the last preinfarction angina and microvascular reperfusion in patients with recanalized acute myocardial infarction. Jpn Heart J. 2003;44:845-854. (Pubitemid 41518941)
29. Takahashi T, Anzai T, Yoshikawa T, Maekawa Y, Asakura Y, Satoh T, Mitamura H, Ogawa S. Effect of preinfarction angina pectoris on ST-segment resolution after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol. 2002;90: 465-469. (Pubitemid 35246033)
30. Jesel L, Morel O, Ohlmann P, Germain P, Faure A, Jahn C, Coulbois PM, Chauvin M, Bareiss P, Roul G. Role of pre-infarction angina and inflammatory status in the extent of microvascular obstruction detected by MRI in myocardial infarction patients treated by PCI. Int J Cardiol. 2007;121:139-147. (Pubitemid 47379451)
31. Dayton C, Yamaguchi T, Warren A, Korthuis RJ. Ischemic preconditioning prevents postischemic arteriolar, capillary, and postcapillary venular dysfunction: signaling pathways mediating the adaptive metamorphosis to a protected phenotype in preconditioned endothelium. Microcirculation. 2002;9:73-89. (Pubitemid 135684684)
32. Sejersten M, Birnbaum Y, Ripa RS, Maynard C, Wagner GS, Clemmensen P. Influences of electrocardiographic ischaemia grades and symptom duration on outcomes in patients with acute myocardial infarction treated with thrombolysis versus primary percutaneous coronary intervention: results from the DANAMI-2 trial. Heart. 2006;92:1577-1582. (Pubitemid 44629159)
33. Higashikuni Y, Tanabe K, Tanimoto S, Aoki J, Yamamoto H, Nakazawa G, Chihara R, Onuma Y, Otsuki S, Yagishita A, Yachi S, Nakajima H, Hara K. Difference of culprit plaque composition between patients with and without pre-infarction angina: an intravascular ultrasound radiofrequency analysis. EuroIntervention. 2009;5:363-369.
34. Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, Weng D, Shah PK, Badimon L. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol. 1994;23:1562-1569. (Pubitemid 24182120)
35. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997;95:594-599. (Pubitemid 27063034)
36. Kojima S, Nonogi H, Miyao Y, Miyazaki S, Goto Y, Itoh A, Daikoku S, Matsumoto T, Morii I, Yutani C. Is preinfarction angina related to the presence or absence of coronary plaque rupture? Heart. 2000;83:64-68. (Pubitemid 30307642)
37. Capone G, Wolf NM, Meyer B, Meister SG. Frequency of intracoronary filling defects by angiography in angina pectoris at rest. Am J Cardiol. 1985;56:403-406. (Pubitemid 15238051)
38. Harjai KJ, Mehta RH, Stone GW, Boura JA, Grines L, Brodie BR, Cox DA, O'Neill WW, Grines CL. Does proximal location of culprit lesion confer worse prognosis in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction? J Interv Cardiol. 2006;19:285-294. (Pubitemid 44185816)
39. Gibson CM, Kirtane AJ, Murphy SA, Karha J, Cannon CP, Giugliano RP, Roe MT, Harrington RA, Ohman EM, Antman EM. Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture. J Thromb Thrombolysis. 2003;15:189-196. (Pubitemid 38213188)
40. Wang JC, Normand SL, Mauri L, Kuntz RE. Coronary artery spatial distribution of acute myocardial infarction occlusions. Circulation. 2004;110:278-284. (Pubitemid 38960797)
41. Henriques JP, Zijlstra F, Otervanger JP, de Boer MJ, van't Hof AW, Hoorntje JC, Suryapranta H. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J. 2002;23:1112-1117. (Pubitemid 35230716)
42. Karila-Cohen D, Czitrom D, Brochet E, Faraggi M, Seknadji P, Himbert D, Juliard JM, Assayag P, Steg PG. Decreased no-reflow in patients with anterior myocardial infarction and pre-infarction angina. Eur Heart J. 1999;20:1724-1730.
43. Iglesias-Garriz I, Corral F, Rodriguez MA, Garrote C, Montes M, Sevillano E. Pre-infarction angina elicits greater myocardial viability on reperfusion after myocardial infarction: a dobu tamine stress echocardiographic study. J Am Coll Cardiol. 2001;37: 1846-1850. (Pubitemid 32499969)
44. Tomoda H, Aoki N. Comparison of protective effects of preinfarction angina pectoris in acute myocardial infarction treated by thrombolysis versus by primary coronary angioplasty with stenting. Am J Cardiol. 1999;84:621-625. (Pubitemid 29417950)
45. Godicke J, Flather M, Noc M, Gyongyosi M, Arntz HR, Grip L, Gabriel HM, Huber K, Nugara F, Schroder J, Svensson L, Wang D, Zorman S, Montalescot G. Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies. Am Heart J. 2005;150:1015.
46. Hassan AK, Liem SS, van der Kley F, Bergheanu SC, Wolterbeek R, Bosch J, Bootsma M, Zeppenfeld K, van der Laarse A, Atsma DE, Jukema JW, Schalij MJ. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program. Catheter Cardiovasc Interv. 2009;74:335-343.
47. Maioli M, Bellandi F, Leoncini M, Toso A, Dabizzi RP. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). J Am Coll Cardiol. 2007;49:1517-1524. (Pubitemid 46517954)
48. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Banuelos C, Hernandez-Antolin R, Escaned J, Moreno R, Alfonso F, Macaya C. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J. 2004;25:1903-1910. (Pubitemid 39452607)
49. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, Giugliano RP, McCabe CH, Braunwald E. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102:2031-2037.
50. Bhatt DL, Harrington RA. A Clinical Trial to Demonstrate the Efficacy of Cangrelor (PCI). National Institutes of Health/Clinicaltrials gov/identifier:NCT00305162. http://www.clinicaltrials. gov/ct2/show/NCT00305162? term=NCT00305162&rank=1.
51. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV, Jr., Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361:2330-2341.
52. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV, Jr., Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt DL. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361:2318-2329.
53. Topol EJ. Maintenance of Platelet Inhibition With Cangrelor (Bridge). National Institutes of Health/Clinicaltrials gov/identifier:NCT00767507. http://www.clinicaltrials.gov/ct2/show/NCT00767507?term=NCT00767507&rank=1 (30 September 2010).
54. A Study to Determine the Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment. National Institutes of Health/Clinicaltrials gov/identifier:NCT00984113. http://www.clinicaltrials.gov/ct2/show/NCT00984113?term=NCT00984113&rank=1 (30 September 2010).
55. Berger JS, Roe MT, Gibson CM, Kilaru R, Green CL, Melton L, Blankenship JD, Metzger DC, Granger CB, Gretler DD, Grines CL, Huber K, Zeymer U, Buszman P, Harrington RA, Armstrong PW. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J. 2009;158: 998-1004.
56. TRA*CER Executive and Steering Committees: Harrington RA, Van de Werf F, Armstrong PW, Aylward P, Park B, Veltri E, Mahaffey KW, Moliterno DJ, Strony J, Wallentin L, White HD, Diaz R, Aylward P, Huber K, Van de Werf F, Nicolau JC, Armstrong PW, Prieto JC, Isaza D, Widimsky P, Grande P, Nieminen M, Montalescot G, Bode C, Wong L, Ofner P, Lewis BS, Ambrosio G, Valgimigli M, Ogawa H, Yamaguchi T, Jukema JW, Cornel JH, White HD, Nordrehaug JE, Ruzyllo W, Providencia L, Tan HC, Dalby A, Seung-Jung P, Betriu A, Cequier A, Held C, Pfisterer M, Chen MF, Timurkaynak T, Storey RF, Chen E, Harrington RA, Hudson MP, Lincoff AM, Mahaffey KW, Morrow DA, Tricoci P, Whellan D. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. Am Heart J. 2009;158:327-334.
57. Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, Bonaca MP, Fish P, McCabe CH, Braunwald E. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J. 2009;158:335-341.
58. A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease. National Institutes of Health/Clinicaltrials gov/identifier: NCT00540670. http://www.clinicaltrials. gov/ct2/show/NCT00540670?term= NCT00540670&rank=1 (30 September 2010).
59. A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome. National Institutes of Health/Clinicaltrials gov/identifier: NCT00619164. http://www.clinicaltrials. gov/ct2/show/NCT00619164?term= NCT00619164&rank=1 (30 September 2010).